Immunovaccine Forms Inaugural Scientific and Clinical Advisory Committee
June 14 2017 - 7:05AM
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, today announced it has formed an inaugural
Scientific and Clinical Advisory Committee (SCAC) comprised of
academic and industry experts in disease areas in which
Immunovaccine focuses: immuno-oncology and virology.
The Committee will provide counsel for the company’s research
and development activities and access to cutting-edge ideas through
collaborative data sharing and insight. Committee members will also
help shape clinical programs based on real-world successes and
unbiased perspectives that are founded in deep clinical research
and field experience.
“We’re honored to have assembled a team of distinguished
industry researchers, clinicians and collaborators to help guide
strategy as we advance and expand our research and clinical
programs,” said Frederic Ors, Immunovaccine’s Chief Executive
Officer. “Each member brings an impressive pedigree and expertise
that directly supports the disease indications we are targeting
using our proprietary DepoVax™ platform. With backgrounds in
virology, immunotherapy and infectious diseases, their collective
experience will be invaluable as we work to bring much-needed
therapies to the market for patients.”
The Scientific and Clinical Advisory Committee members
include:
Barney Graham, PhD, MDSenior Investigator,
Viral Pathogenesis Laboratory, National Institute of Allergy and
Infectious Diseases Vaccine Research CenterNational Institutes of
Health
Scott Halperin, MDDirectorCanadian Centre for
Vaccinology
Ramy Ibrahim, MDVice President, Clinical
DevelopmentParker Institute for Cancer Immunotherapy
James Johnston, MB, BCh, FRCPCSenior Scientist,
Research Institute in Oncology and HematologyCancer Care
Manitoba
Grant McFadden, PhDDirector, Biodesign Center
for Immunotherapy, Vaccines and Virotherapy Arizona State
University
Michael Aaron Morse,
MDProfessor of Medicine and Professor in
the Department of Surgery Duke University Medical Center
Brad Nelson, PhDDirector and Distinguished
Scientist, Deeley Research CentreBC Cancer Agency
Kunle Odunsi, PhD, MD, FRCOG, FACOGCancer
Center Deputy Director; Chair of the Department of Gynecologic
Oncology; and Executive Director, Center for ImmunotherapyRoswell
Park Cancer Institute
David Spaner, PhD, MDSenior Scientist,
Biological Sciences, Odette Cancer Research ProgramSunnybrook
Research Institute
Pramod Srivastava, PhD, MDDirector, Center for
Immunotherapy of Cancer and Infectious DiseasesEversource Energy
Chair in Experimental OncologyDirector of The Carole and Ray Neag
Comprehensive Cancer Center University of Connecticut School of
Medicine
About ImmunovaccineImmunovaccine Inc. is a
clinical-stage biopharmaceutical company dedicated to making
immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and infectious diseases.
Immunovaccine develops T cell activating cancer immunotherapies and
infectious disease vaccines based on DepoVax, the Company’s
patented platform that provides controlled and prolonged exposure
of antigens and adjuvant to the immune system. Immunovaccine has
advanced two T cell activation therapies for cancer through Phase 1
human clinical trials and is currently conducting a Phase 1b study
with Incyte Corporation assessing lead cancer therapy,
DPX-Survivac, as a combination therapy in ovarian cancer. The
Company is also exploring additional applications of DepoVax,
including DPX-RSV, an innovative vaccine candidate for respiratory
syncytial virus (RSV), which has recently completed a Phase 1
clinical trial. Immunovaccine also has ongoing clinical projects to
assess the potential of DepoVax to address malaria and the Zika
virus. Connect at www.imvaccine.com.
Immunovaccine Forward-Looking StatementsThis
press release contains forward-looking information under applicable
securities law. All information that addresses activities or
developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Company, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Contacts for Immunovaccine:
MEDIA
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONS
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: info@imvaccine.com
Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572 E: patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024